2,9-DICHLORO-QUINO[2,2,9-二氯喹啉并[2,3-B]吖啶-6,7,13,14(5H,12H)-四酮 | 2490-60-0

• 物质功能分类: 医药中间体 - 杂环化合物 - 喹啉类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 2,9-DICHLORO-QUINO[2,2,9-二氯喹啉并[2,3-B]吖啶-6,7,13,14(5H,12H)-四酮
• 英文名称: 2,9-Dichlor-chinacridonchinon
• 英文别名: 2,9-Dichlor-lin.-trans-chinacridonchinon；2,9-dichloro-5H,12H-quino[2,3-b]acridine-6,7,13,14-tetraone；2,9-dichloroquino[2,3-b]acridine-6,7,13,14(5H,12H)-tetrone；Quino[2,3-b]acridine-6,7,13,14(5H,12H)-tetrone, 2,9-dichloro-；2,9-dichloro-5,12-dihydroquinolino[2,3-b]acridine-6,7,13,14-tetrone
• CAS: 2490-60-0
• 化学式: C₂₀H₈Cl₂N₂O₄
• 分子量: 411.201
• InChiKey: LGVIDCRFSIRUGG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  28
• 可旋转键数：
  0
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  92.3
• 氢给体数：
  2
• 氢受体数：
  6

安全信息

• 海关编码：
  2933990090

文献信息

• TREATMENTS FOR NEUROPATHY
  申请人：Children's Medical Center Corporation

  公开号：EP2240177A2

  公开（公告）日：2010-10-20
• Treatments for Neuropathy
  申请人：Corfas Gabriel

  公开号：US20110086878A1

  公开（公告）日：2011-04-14

  Small fiber neuropathy is treated or prevented by topically administering to a subject in need thereof topically active quinoline compounds or pharmaceutically acceptable salts thereof under conditions effective to treat or prevent neuropathy in the subject. Glial cell-derived neurotrophic factor (GDNF) receptors are modulated with the subject active quinoline compounds, which may be formulated in topical lotions.
• COMPOSITIONS AND METHODS FOR TREATING NEUROPATHY
  申请人：CHILDEREN'S MEDICAL CENTER CORPORATION

  公开号：US20160045487A1

  公开（公告）日：2016-02-18

  The invention features XIB4035 for the treatment of large fiber neuropathy, and combinations of XIB4035 and GDNF for the treatment of both large and small fiber neuropathies.
• US7863295B2
  申请人：——

  公开号：US7863295B2

  公开（公告）日：2011-01-04
• [EN] TREATMENTS FOR NEUROPATHY<br/>[FR] TRAITEMENTS DE LA NEUROPATHIE
  申请人：CHILDRENS MEDICAL CENTER

  公开号：WO2009102570A2

  公开（公告）日：2009-08-20

  Small fiber neuropathy is treated or prevented by topically administering to a subject in need thereof topically active quinoline compounds or pharmaceutically acceptable salts thereof under conditions effective to treat or prevent neuropathy in the subject. Glial cell- derived neurotrophic factor (GDNF) receptors are modulated with the subject active quinoline compounds, which may be formulated in topical lotions.